Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management

References

• Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40 Suppl 2:S253–9.
   PubMedGoogle Scholar
• Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–22.
   PubMed Web of Science ®Google Scholar
• Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007;10:178–84.
   PubMedGoogle Scholar
• Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2008;10:597–605.
   PubMedGoogle Scholar
• Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, . Extraintestinal manifestations of Crohn's disease. Digestion. 2007;76:141–8.
   PubMedGoogle Scholar
• Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol. 2006;40:467–75.
   PubMedGoogle Scholar
• Meier C, Plevy S. Therapy insight: how the gut talks to the joints-inflammatory bowel disease and the spondyloarthropathies. Nat Clin Pract Rheumatol. 2007;3:667–74.
   PubMedGoogle Scholar
• Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, . Extraintestinal manifestations in inflamma-tory bowel disease. World J Gastroenterol. 2005;11:7227–36.
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin Arthritis Rheum. 2008;38:83–100.
   PubMed Web of Science ®Google Scholar
• Padovan M, Castellino G, Govoni M, Trotta F. The treatment of the rheumatological manifestations of the inflammatory bowel diseases. Rheumatol Int. 2006;26:953–8.
   PubMedGoogle Scholar
• Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet. 1993;342:646–50.
   PubMed Web of Science ®Google Scholar
• Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, . The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359–64.
   PubMed Web of Science ®Google Scholar
• Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118:274–8.
   PubMed Web of Science ®Google Scholar
• O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353–64.
   PubMed Web of Science ®Google Scholar
• Laukens D, Peeters H, Marichal D, Vander Cruyssen B, Mielants H, Elewaut D, . CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis. 2005;64:930–5.
   PubMed Web of Science ®Google Scholar
• Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. Annu Rev Med. 2007;58:401–16.
   PubMed Web of Science ®Google Scholar
• Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol. 2009;104:1298–313.
   PubMed Web of Science ®Google Scholar
• Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009;65:963–70.
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, . The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68 Suppl 2:ii1–44.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol. 2007;13:6156–65.
   PubMedGoogle Scholar
• Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004;39:145–53.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:797–813.
   PubMed Web of Science ®Google Scholar
• Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15:323–8.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228–33.
   PubMed Web of Science ®Google Scholar
• Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313–9.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi PG. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med. 2000;247:63–70.
   PubMedGoogle Scholar
• Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, . Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol. 1999;94:1292–7.
   PubMed Web of Science ®Google Scholar
• Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis. 2002;8:87–92.
   PubMed Web of Science ®Google Scholar
• Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203–8.
   PubMed Web of Science ®Google Scholar
• Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:268–75.
   PubMed Web of Science ®Google Scholar
• Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995;37:71–6.
   PubMed Web of Science ®Google Scholar
• Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2005;CD000227.
   Google Scholar
• Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther. 2003;18:1121–7.
   PubMed Web of Science ®Google Scholar
• Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendro-nate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 2000;119:639–46.
   PubMedGoogle Scholar
• Stokkers PC, Deley M, Van Der Spek M, Verberne HJ, van Deventer SJ, Hommes DW. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Scand J Gastroenterol. 2006;41:200–4.
   PubMed Web of Science ®Google Scholar
• Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut. 1993;34:1543–6.
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, . Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26:688–703.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003;15:857–64.
   PubMed Web of Science ®Google Scholar
• Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporos Int. 1993;3:236–41.
   PubMed Web of Science ®Google Scholar
• Compston JE, Ayers AB, Horton LW, Tighe JR, Creamer B. Osteomalacia after small-intestinal resection. Lancet. 1978;1:9–12.
   PubMed Web of Science ®Google Scholar
• Basha B, Rao DS, Han ZH, Parfitt AM. Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. Am J Med. 2000;108:296–300.
   PubMed Web of Science ®Google Scholar
• Lopez I, Buchman AL. Metabolic bone disease in IBD. Curr Gastroenterol Rep. 2000;2:317–22.
   PubMedGoogle Scholar
• Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol. 1995;7:609–14.
   PubMed Web of Science ®Google Scholar
• Timani S, Mutasim DF. Skin manifestations of inflamma-tory bowel disease. Clin Dermatol. 2008;26:265–73.
   PubMed Web of Science ®Google Scholar
• Tromm A, May D, Almus E, Voigt E, Greving I, Schwegler U, . Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol. 2001;39:137–44.
   PubMedGoogle Scholar
• Yuksel I, Basar O, Ataseven H, Ertugrul I, Arhan M, Ibis M, . Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:546–50.
   PubMedGoogle Scholar
• Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1424–9.
   PubMed Web of Science ®Google Scholar
• Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580–5.
   PubMed Web of Science ®Google Scholar
• Agrawal D, Rukkannagari S, Kethu S. Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol Dietol. 2007;53:233–48.
   PubMedGoogle Scholar
• Campbell S, Cripps S, Jewell DP. Therapy Insight: pyoderma gangrenosum—old disease, new management. Nat Clin Pract Gastroenterol Hepatol. 2005;2:587–94.
   PubMedGoogle Scholar
• Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409.
   PubMed Web of Science ®Google Scholar
• Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273–83.
   PubMed Web of Science ®Google Scholar
• Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29–34.
   PubMed Web of Science ®Google Scholar
• Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581–5.
   PubMed Web of Science ®Google Scholar
• Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, . Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–9.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821–6.
   PubMed Web of Science ®Google Scholar
• Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol. 2008;66:618–25.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Vainer B, Rask-Madsen J. Non-IBD and non-infectious colitis. Nat Clin Pract Gastroenterol Hepatol. 2008;5:28–39.
   PubMedGoogle Scholar
• Rodriguez M, Rubio JA, Sanchez R. Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis. Oral Dis. 2007;13:490–4.
   PubMed Web of Science ®Google Scholar
• Yiasemides E, Thom G. Azathioprine hypersensitivity presenting as a neutrophilic dermatosis in a man with ulcerative colitis. Australas J Dermatol. 2009;50:48–51.
   PubMed Web of Science ®Google Scholar
• Cohen PR. Sweet's syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.
   PubMed Web of Science ®Google Scholar
• Urlep D, Mamula P, Baldassano R. Extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol Dietol. 2005;51:147–63.
   PubMedGoogle Scholar
• Kemmett D, Hunter JA. Sweet's syndrome: a clinicopatho-logic review of twenty-nine cases. J Am Acad Dermatol. 1990;23:503–7.
   PubMedGoogle Scholar
• Foster EN, Nguyen KK, Sheikh RA, Prindiville TP. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin Dev Immunol. 2005;12:145–9.
   PubMedGoogle Scholar
• Felekis T, Katsanos K, Kitsanou M, Trakos N, Theopistos V, Christodoulou D, . Spectrum and frequency of ophthal-mologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis. 2009;15:29–34.
   PubMed Web of Science ®Google Scholar
• Ghanchi FD, Rembacken BJ. Inflammatory bowel disease and the eye. Surv Ophthalmol. 2003;48:663–76.
   PubMed Web of Science ®Google Scholar
• Yilmaz S, Aydemir E, Maden A, Unsal B. The prevalence of ocular involvement in patients with inflammatory bowel disease. Int J Colorectal Dis. 2007;22:1027–30.
   PubMedGoogle Scholar
• Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135–9.
   PubMed Web of Science ®Google Scholar
• Ally MR, Veerappan GR, Koff JM. Treatment of recurrent Crohn's uveitis with infliximab. Am J Gastroenterol. 2008;103:2150–1.
   PubMed Web of Science ®Google Scholar
• Fries W, Giofre MR, Catanoso M, Lo GR. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol. 2002;97:499–500.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130:469–76.
   PubMed Web of Science ®Google Scholar
• Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol. 1994;118:601–11.
   PubMedGoogle Scholar
• Kurz PA, Suhler EB, Choi D, Rosenbaum JT. Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol. 2009;93:546–8.
   PubMed Web of Science ®Google Scholar
• Michalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep. 2008;8:339–47.
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Schrumpf E, Boberg KM. Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol. 2007;13:5421–31.
   PubMed Web of Science ®Google Scholar
• Bergquist A, Said K, Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol. 2007;42:88–93.
   PubMed Web of Science ®Google Scholar
• Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol. 1994;21:787–91.
   PubMed Web of Science ®Google Scholar
• Takikawa H. Recent status of primary sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Surg. 1999;6:352–5.
   PubMedGoogle Scholar
• Olsson R, Danielsson A, Jarnerot G, Lindstrom E, Loof L, Rolny P, . Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100:1319–23.
   PubMed Web of Science ®Google Scholar
• Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol. 2007;102:107–14.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–9.
   PubMed Web of Science ®Google Scholar
• Florin TH, Pandeya N, Radford-Smith GL. Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut. 2004;53:973–9.
   PubMedGoogle Scholar
• Berstad AE, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2006;4:514–20.
   PubMed Web of Science ®Google Scholar
• Meagher S, Yusoff I, Kennedy W, Martel M, Adam V, Barkun A. The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis. Endoscopy. 2007;39:222–8.
   PubMed Web of Science ®Google Scholar
• Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol. 1997;32:604–10.
   PubMed Web of Science ®Google Scholar
• Smith T, Befeler AS. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Curr Gastroenterol Rep. 2007;9:54–9.
   PubMedGoogle Scholar
• Vacca M, Krawczyk M, Petruzzelli M, Sasso RC, van Erpecum KJ, Palasciano G, . Current treatments of primary sclerosing cholangitis. Curr Med Chem. 2007;14:2081–94.
   PubMedGoogle Scholar
• Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–93.
   PubMed Web of Science ®Google Scholar
• Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Speck M, . A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42:522–6.
   PubMed Web of Science ®Google Scholar
• Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver. 2000;20:97–103.
   PubMedGoogle Scholar
• Tamura S, Sugawara Y, Kaneko J, Matsui Y, Togashi J, Makuuchi M. Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int. 2007;27:86–94.
   PubMed Web of Science ®Google Scholar
• Nemeth A, Ejderhamn J, Glaumann H, Strandvik B. Liver damage in juvenile inflammatory bowel disease. Liver. 1990;10:239–48.
   PubMedGoogle Scholar
• Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci. 2007;52:3123–35.
   PubMed Web of Science ®Google Scholar
• Heaton KW, Read AE. Gall stones in patients with disorders of the terminal ileum and disturbed bile salt metabolism. Br Med J. 1969;3:494–6.
   PubMed Web of Science ®Google Scholar
• Baker AL, Kaplan MM, Norton RA, Patterson JF. Gallstones in inflammatory bowel disease. Am J Dig Dis. 1974;19:109–12.
   PubMedGoogle Scholar
• Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, . Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417–20.
   PubMed Web of Science ®Google Scholar
• Fraquelli M, Losco A, Visentin S, Cesana BM, Pometta R, Colli A, . Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med. 2001;161:2201–4.
   PubMedGoogle Scholar
• Lapidus A, Bangstad M, Astrom M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol. 1999;94:1261–6.
   PubMed Web of Science ®Google Scholar
• Jones MR, Gregory D, Evans KT, Rhodes J. The prevalence of gallbladder disease in patients with ileostomy. Clin Radiol. 1976;27:561–2.
   PubMedGoogle Scholar
• Lorusso D, Leo S, Mossa A, Misciagna G, Guerra V. Cholelithiasis in inflammatory bowel disease. A case-control study. Dis Colon Rectum. 1990;33:791–4.
   PubMed Web of Science ®Google Scholar
• Kratzer W, Haenle MM, Mason RA, von Tirpitz C, Kaechele V. Prevalence of cholelithiasis in patients with chronic inflamma-tory bowel disease. World J Gastroenterol. 2005;11:6170–5.
   PubMedGoogle Scholar
• Parente F, Pastore L, Bargiggia S, Cucino C, Greco S, Molteni M, . Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology. 2007;45:1267–74.
   PubMed Web of Science ®Google Scholar
• Ertan A. Treatment of gallstones by extracorporeal shock wave lithotripsy. Am J Gastroenterol. 2002;97:831–2.
   PubMedGoogle Scholar
• Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116 Suppl 7A:44S–9S.
   PubMedGoogle Scholar
• Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000;6:142–50.
   PubMed Web of Science ®Google Scholar
• Rockey DC. Occult gastrointestinal bleeding. N Engl J Med. 1999;341:38–46.
   PubMedGoogle Scholar
• Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol. 2001;96:2296–8.
   PubMed Web of Science ®Google Scholar
• Giannini S, Martes C. Anemia in inflammatory bowel disease. Minerva Gastroenterol Dietol. 2006;52:275–91.
   PubMedGoogle Scholar
• Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005;3:617–28.
   PubMed Web of Science ®Google Scholar
• Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, . Is inflammatory bowel disease an independent and disease specific risk factor for thromboem-bolism? Gut. 2004;53:542–8.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Sam J. Rising prevalence of venous throm-boembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272–80.
   PubMed Web of Science ®Google Scholar
• Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97–101.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430–4.
   PubMed Web of Science ®Google Scholar
• Erzin Y, Uzun H, Celik AF, Aydin S, Dirican A, Uzunismail H. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications. J Clin Gastroenterol. 2008;42:481–6.
   PubMed Web of Science ®Google Scholar
• Jensen OK, Rasmussen C, Mollerup F, Christensen PB, Hansen H, Ekelund S, . Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation. J Rheumatol. 2002;29:1615–8.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:160–70.
   PubMedGoogle Scholar
• Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–46.
   PubMed Web of Science ®Google Scholar
• Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr. 2004;24:539–77.
   PubMed Web of Science ®Google Scholar
• Phelip JM, Ducros V, Faucheron JL, Flourie B, Roblin X. Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:242–8.
   PubMed Web of Science ®Google Scholar
• Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, . DACH-LIGA homocystein (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003;41:1392–403.
   PubMed Web of Science ®Google Scholar
• Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol. 2000;95:2825–30.
   PubMedGoogle Scholar
• Sato S, Sasaki I, Naito H, Funayama Y, Fukushima K, Shibata C, . Management of urinary complications in Crohn's disease. Surg Today. 1999;29:713–7.
   PubMedGoogle Scholar
• Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998;93:504–14.
   PubMed Web of Science ®Google Scholar
• Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379–400.
   PubMed Web of Science ®Google Scholar
• McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002;89:835–41.
   PubMedGoogle Scholar
• Miller NL, Lingeman JE. Management of kidney stones. BMJ. 2007;334:468–72.
   PubMed Web of Science ®Google Scholar
• Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155:839–43.
   PubMed Web of Science ®Google Scholar
• Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 1986;30:422–8.
   PubMedGoogle Scholar
• Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997;158:2069–73.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315:1386–9.
   PubMed Web of Science ®Google Scholar
• Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand. 1984;215:383–9.
   PubMed Web of Science ®Google Scholar
• Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol. 1999;13:679–85.
   PubMed Web of Science ®Google Scholar
• Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Fukukita S, . Bronchopulmonary disease in ulcerative colitis. Intern Med. 1992;31:1155–9.
   PubMedGoogle Scholar
• Gionchetti P, Schiavina M, Campieri M, Fabiani A, Cornia BM, Belluzzi A, . Bronchopulmonary involvement in ulcerative colitis. J Clin Gastroenterol. 1990;12:647–50.
   PubMedGoogle Scholar
• Moles KW, Varghese G, Hayes JR. Pulmonary involvement in ulcerative colitis. Br J Dis Chest. 1988;82:79–83.
   PubMedGoogle Scholar
• Higenbottam T, Cochrane GM, Clark TJ, Turner D, Millis R, Seymour W. Bronchial disease in ulcerative colitis. Thorax. 1980;35:581–5.
   PubMedGoogle Scholar
• Kuzela L, Vavrecka A, Prikazska M, Drugda B, Hronec J, Senkova A, . Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterology. 1999;46:1714–9.
   PubMedGoogle Scholar
• Marvisi M, Borrello PD, Brianti M, Fornarsari G, Marani G, Guariglia A. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J. 2000;16:965–8.
   PubMedGoogle Scholar
• Songur N, Songur Y, Tuzun M, Dogan I, Tuzun D, Ensari A, . Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol. 2003;37:292–8.
   PubMedGoogle Scholar
• Tzanakis N, Samiou M, Bouros D, Mouzas J, Kouroumalis E, Siafakas NM. Small airways function in patients with inflammatory bowel disease. Am J Respir Crit Care Med. 1998;157:382–6.
   PubMedGoogle Scholar
• Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:104–15.
   PubMed Web of Science ®Google Scholar
• Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:122S–31S.
   PubMedGoogle Scholar
• Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:104S–15S.
   PubMed Web of Science ®Google Scholar
• Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, . Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;CD001387.
   Google Scholar
• Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, . A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–24.
   PubMed Web of Science ®Google Scholar
• Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol. 1993;17:286–91.
   PubMedGoogle Scholar
• Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, . Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94:2141–8.
   PubMed Web of Science ®Google Scholar
• Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV Jr. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009;15:1326–30.
   PubMed Web of Science ®Google Scholar
• Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf. 2008;31:823–37.
   PubMed Web of Science ®Google Scholar
• Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, . Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:771–7.
   PubMedGoogle Scholar
• Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429–48.
   PubMed Web of Science ®Google Scholar
• Stocker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stocker K, . Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl. 1987;139:41–52.
   PubMedGoogle Scholar
• Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol. 2003;98:1305–8.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercap-topurine or azathioprine. Aliment Pharmacol Ther. 2001;15:1699–708.
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641–9.
   PubMed Web of Science ®Google Scholar
• Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, van Haastert M, Ploeg RJ, . Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther. 2004;20:843–50.
   PubMed Web of Science ®Google Scholar
• Weersma RK, Batstra MR, Kleibeuker JH, van Dullemen HM. Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease? JOP. 2008;9:283–9.
   PubMedGoogle Scholar